EditorialHuman Studies
Improved Prospects for Cancer Therapy with Radiolabeled Antibody Fragments and Peptides?
Thomas M. Behr and David M. Goldenberg
Journal of Nuclear Medicine May 1996, 37 (5) 834-836;


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Improved Prospects for Cancer Therapy with Radiolabeled Antibody Fragments and Peptides?
Thomas M. Behr, David M. Goldenberg
Journal of Nuclear Medicine May 1996, 37 (5) 834-836;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN)
- [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
- Novel Series of 111In-Labeled Bombesin Analogs as Potential Radiopharmaceuticals for Specific Targeting of Gastrin-Releasing Peptide Receptors Expressed on Human Prostate Cancer Cells
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs
- FDG PET and Immunoscintigraphy with 99mTc-Labeled Antibody Fragments for Detection of the Recurrence of Colorectal Carcinoma